LU91254I2 - Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr) - Google Patents

Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)

Info

Publication number
LU91254I2
LU91254I2 LU91254C LU91254C LU91254I2 LU 91254 I2 LU91254 I2 LU 91254I2 LU 91254 C LU91254 C LU 91254C LU 91254 C LU91254 C LU 91254C LU 91254 I2 LU91254 I2 LU 91254I2
Authority
LU
Luxembourg
Prior art keywords
daptomycin
administering
muscle toxicity
skeletal muscle
effective amount
Prior art date
Application number
LU91254C
Other languages
English (en)
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91254(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of LU91254I2 publication Critical patent/LU91254I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
LU91254C 1998-09-25 2006-06-28 Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr) LU91254I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US12575099P 1999-03-24 1999-03-24
PCT/US1999/022366 WO2000018419A2 (fr) 1998-09-25 1999-09-24 Methodes d'administration d'antibiotiques

Publications (1)

Publication Number Publication Date
LU91254I2 true LU91254I2 (fr) 2006-08-28

Family

ID=26798675

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91254C LU91254I2 (fr) 1998-09-25 2006-06-28 Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)

Country Status (26)

Country Link
US (2) US6468967B1 (fr)
EP (2) EP1115417B1 (fr)
JP (4) JP4184607B2 (fr)
KR (2) KR20100051735A (fr)
CN (2) CN1150029C (fr)
AT (1) ATE322280T1 (fr)
AU (1) AU764348B2 (fr)
BR (1) BR9914051A (fr)
CA (1) CA2344318C (fr)
CY (3) CY1105556T1 (fr)
DE (3) DE122006000049I2 (fr)
DK (2) DK1115417T3 (fr)
ES (2) ES2603086T3 (fr)
HK (1) HK1040363B (fr)
HU (1) HU230656B1 (fr)
IS (2) IS5890A (fr)
LU (1) LU91254I2 (fr)
NL (1) NL300232I2 (fr)
NO (1) NO20011454L (fr)
NZ (1) NZ510690A (fr)
PL (2) PL206091B1 (fr)
PT (2) PT1674107T (fr)
RU (1) RU2363489C9 (fr)
SI (2) SI1115417T1 (fr)
TR (1) TR200100841T2 (fr)
WO (1) WO2000018419A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL206091B1 (pl) 1998-09-25 2010-06-30 Cubist Pharmaceuticals Zastosowania daptomycyny
EP2295444A3 (fr) 1999-12-15 2011-03-23 Cubist Pharmaceutical Inc. Lipopeptides en tant qu'agents antibactériens
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
KR20080036661A (ko) 2000-12-18 2008-04-28 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (fr) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Procedes de preparation de lipopeptides purifies
EP1932853A1 (fr) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Nouveaux depsipeptides et leur procédé de préparation
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (fr) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Composition pharmaceutique, substrat comprenant une composition pharmaceutique et utilisation d'une composition pharmaceutique
MX2010009628A (es) * 2008-03-04 2010-09-28 Elan Pharma Int Ltd Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
MX2011000696A (es) 2008-07-17 2011-07-29 Acorda Therapeutics Inc Dosificacion terapeutica de una neurregulina o una subsecuencia de la misma para el tratamiento o la profilaxis de insuficiencia cardiaca.
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
WO2010048630A1 (fr) * 2008-10-24 2010-04-29 Los Angeles Biomedical Reserch Institute At Harbor-Ucla Medical Center Hydroxy-phényl-benzoates anti-infection et leurs procédés d'uutilisation
EP2674437A1 (fr) * 2008-12-22 2013-12-18 Cubist Pharmaceuticals, Inc. Nouveaux agents antibactériens pour le traitement d'infections GRAM positives
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
CA2767614C (fr) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Schemas posologiques de l'acide fusidique pour le traitement d'infections bacteriennes
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CA2773033C (fr) 2009-09-04 2016-10-11 Mpex Pharmaceuticals, Inc. Utilisation de levofloxacine en aerosol pour traiter la fibrose kystique
FI2504353T4 (fi) 2009-11-23 2023-11-30 Cubist Pharmaceuticals Llc Lipopeptidikoostumukset ja vastaavat menetelmät
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
ES2552754T1 (es) * 2012-09-11 2015-12-02 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
TWI641372B (zh) 2013-03-15 2018-11-21 美商梅琳塔有限責任公司 使用抗生素治療超重和肥胖患者感染的方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
JP2019515007A (ja) * 2016-05-13 2019-06-06 スペロ ポテンシエーター インコーポレイテッドＳｐｅｒｏ Ｐｏｔｅｎｔｉａｔｏｒ， Ｉｎｃ． 新規カチオン性ペプチドｓｐｒ７４１による、抗生物質活性の増強
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
CA1315229C (fr) 1987-06-10 1993-03-30 Patrick J. Baker Procede de purification chromatographique
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
NZ232763A (en) * 1989-03-06 1991-09-25 Lilly Co Eli Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
PL206091B1 (pl) 1998-09-25 2010-06-30 Cubist Pharmaceuticals Zastosowania daptomycyny
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
NO20011454L (no) 2001-05-25
NZ510690A (en) 2002-10-25
PT1115417E (pt) 2006-07-31
AU6268799A (en) 2000-04-17
CN1150029C (zh) 2004-05-19
EP1674107B1 (fr) 2016-08-24
HK1040363A1 (en) 2002-06-07
JP2003321389A (ja) 2003-11-11
JP4184607B2 (ja) 2008-11-19
DE69930758T2 (de) 2007-04-26
AU764348B2 (en) 2003-08-14
NO20011454D0 (no) 2001-03-22
TR200100841T2 (tr) 2002-01-21
WO2000018419A2 (fr) 2000-04-06
HUP0103874A3 (en) 2002-09-30
CY1118334T1 (el) 2017-06-28
DK1115417T3 (da) 2006-07-31
EP1674107A8 (fr) 2006-10-04
DE122006000049I2 (de) 2007-11-08
CY2006003I2 (el) 2009-11-04
EP1115417B1 (fr) 2006-04-05
CY1105556T1 (el) 2010-07-28
CN1530136A (zh) 2004-09-22
JP2006335773A (ja) 2006-12-14
RU2363489C2 (ru) 2009-08-10
ATE322280T1 (de) 2006-04-15
HU230656B1 (hu) 2017-06-28
KR20010075327A (ko) 2001-08-09
EP1674107B8 (fr) 2017-01-25
PL206091B1 (pl) 2010-06-30
JP2004339238A (ja) 2004-12-02
BR9914051A (pt) 2001-06-19
CA2344318C (fr) 2006-07-04
PL348328A1 (en) 2002-05-20
DE69930758D1 (de) 2006-05-18
DE122006000049I1 (de) 2007-01-04
CY2006003I1 (el) 2009-11-04
SI1674107T1 (sl) 2017-01-31
EP1674107A2 (fr) 2006-06-28
KR20100051735A (ko) 2010-05-17
CA2344318A1 (fr) 2000-04-06
NL300232I2 (nl) 2007-01-02
WO2000018419A3 (fr) 2000-07-06
CN1348382A (zh) 2002-05-08
SI1115417T1 (sl) 2006-08-31
HUP0103874A2 (hu) 2002-02-28
JP2002525335A (ja) 2002-08-13
RU2363489C9 (ru) 2010-03-20
US20020142948A1 (en) 2002-10-03
DK1674107T3 (en) 2016-12-19
US6468967B1 (en) 2002-10-22
PL203689B1 (pl) 2009-11-30
RU2004106569A (ru) 2005-08-10
ES2603086T3 (es) 2017-02-23
ES2259845T3 (es) 2006-10-16
EP1115417A2 (fr) 2001-07-18
IS5890A (is) 2001-03-14
PT1674107T (pt) 2016-12-07
IS8807A (is) 2009-03-10
EP1674107A3 (fr) 2012-06-20
US6852689B2 (en) 2005-02-08
HK1040363B (zh) 2007-01-26
NL300232I1 (nl) 2006-09-01

Similar Documents

Publication Publication Date Title
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
FI935847A (fi) L-DOPA-esterikoostumukset
KR970705553A (ko) 디히드로벤조푸란, 및 항염증 약물로서 유용한 관련 화합물(dihydrobenzofuran and related compounds useful as anti-inflammatory agents)
DK1201246T3 (da) Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
FI923662A (fi) Terapeutiska medel